Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Product overview
Incruse Ellipta is used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle, making it easier for air to get in and out of the lungs. When used regularly, it can help control breathing difficulties and improve health-related quality of life. 1
Safety Information
Dosage & Administration
Incruse Ellipta should be administered as one inhalation at the same time of the day each day.
Contraindications
It is contraindicated in patients hypersensitive to umeclidinum, lactose monohydrate or magnesium stearate.
Adverse events
Treatment with Incruse Ellipta should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Incruse Ellipta should be used with caution in patients with severe cardiovascular disorders, particularly cardiac arrhythmias. Incruse Ellipta should be used with caution in patients with urinary retention or narrow angle glaucoma. Incruse Ellipta is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Common side effects reported with the use of Incruse Ellipta include nasopharyngitis, upper respiratory tract infection, cough, oropharyngeal pain, constipation, sinusitis, headache, tachycardia and urinary tract infection.
Reference:
POM. Further information is available from GlaxoSmithKline (Ireland) Ltd
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies
